Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy
- 17 October 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 22 (22) , 8801-8809
Abstract
Pancreatic cancer immunotherapy is becoming a promising strategy for improving the survival rate of postsurgical patients. However, the low response rate to immunotherapy suggests a low number of antigen-specific T cells and a high number of immunosuppressive tumor-associated macrophages in the pancreatic tumor microenvironment. Herein, we developed an in situ injectable thermosensitive chitosan hydrogel loaded with lipid-immune regulatory factor 5 (IRF5) mRNA/C-C chemokine ligand 5 (CCL5) siRNA (LPR) nanoparticle complexes (LPR@CHG) that reprogram the antitumoral immune niche. The LPR@CHG hydrogel upregulates IRF5 and downregulates CCL5 secretion, which contribute to a significant increase in M1 phenotype macrophages. Tumor growth is controlled by effective M1 phenotype macrophage that initiate T cell-mediated immune responses. Overall, the LPR@CHG hydrogel is expected to be a meaningful immunotherapy platform that can reshape the immunosuppressive tumor microenvironment and improve the efficacy of current pancreatic immunotherapies while minimizing systemic toxicity.Keywords
Funding Information
- Taishan Scholar Project of Shandong Province (Ts20190987)
- National Natural Science Foundation of China (82125026)
- Natural Science Foundation of Shandong Province (ZR2020ZD11)
This publication has 43 references indexed in Scilit:
- Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancerBiomaterials, 2015
- mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discovery, 2014
- The Inflammatory Chemokine CCL5 and Cancer ProgressionMediators of Inflammation, 2014
- Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceNature Medicine, 2013
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapyJournal of Biomaterials Science, Polymer Edition, 2013
- Differential macrophage programming in the tumor microenvironmentTrends in Immunology, 2012
- IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responsesNature Immunology, 2011
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialThe Lancet, 2009
- Inflammation and necrosis promote tumour growthNature Reviews Immunology, 2004